Jonathan Boldt - Inovalon Holdings Vice President - Finance
INOV Etf | USD 28.03 0.05 0.18% |
Mr. Jonathan Boldt CPA, is Chief Financial Officer of the Company. Mr. Boldt has served as our Chief Financial Officer since January 14, 2019. Mr. Boldt previously served as the Companys interim Chief Financial Officer and Vice President of Finance for corporate financial planning and analysis since March 16, 2018. As Chief Financial Officer, Mr. Boldt is responsible for the management, planning, implementation and execution of all financial activities, forecasting, reporting, audit, treasury, tax, and related compliance obligations of the Company. Since joining the Company in 2012, Mr. Boldt has served in numerous expanding financial positions playing integral roles in the Companys Initial Public Offering in 2015, and the acquisitions of Avalere Health, Inc. in 2015, Creehan Holding Co., Inc. in 2016, and ABILITY Network Inc. and its associated term loan financing facility in 2018. Prior to joining the Company in 2012, Mr. Boldt served in a number of escalating roles at Deloitte Touche, LLP, ultimately holding the position of attestation manager for public and private, domestic and international clients in information technology, government contracting, professional services, and manufacturing industries at various growth stages and scale ranging from 200 million to 20 billion in annual revenue. Mr. Boldt graduated magna cum laude from Loyola University in Maryland with a Bachelor degree in accounting and a masters of business administration degree with an information technologies concentration. He serves on the Loyola University of Maryland Sellinger School of Business Joint Advisory Board. Mr. Boldt is an active certified public accountant in the State of Maryland, a status which he has held since 2008.
Age | 33 |
Tenure | 5 years |
Professional Marks | CPA |
Address | 4321 Collington Road, Bowie, MD, United States, 20716 |
Phone | (215) 979-3750 |
Web | http://www.inovalon.com |
Issuer | Innovator Capital Management |
Inception Date | 2023-11-01 |
Benchmark | iShares MSCI EAFE ETF |
Entity Type | Regulated Investment Company |
Asset Under Management | 3.49 Million |
Asset Type | Equity |
Category | Strategy |
Focus | Developed Markets Basket |
Market Concentration | Developed Markets |
Region | Global ex-North America |
Inovalon Holdings Management Efficiency
The company has return on total asset (ROA) of 0.0331 % which means that it generated a profit of $0.0331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0716 %, meaning that it created $0.0716 on every $100 dollars invested by stockholders. Inovalon Holdings' management efficiency ratios could be used to measure how well Inovalon Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
Showing other executives | One Year Return | ||
AmirAli Talasaz | Guardant Health | 44 | |
Yaron Zilberman | Medigus Ltd ADR | 42 | |
Michael Phillips | Cigna Corp | N/A | |
Lisa Uthgenannt | Laboratory | 57 | |
David Erickson | Edwards Lifesciences Corp | N/A | |
John Murabito | Cigna Corp | 62 | |
Herbert Fritch | Cigna Corp | 64 | |
Stephen Farber | Mednax Inc | 49 | |
CHRISTOPHER HOCEVAR | Cigna Corp | 43 | |
Christopher MBA | Cigna Corp | N/A | |
JeanLuc Lemercier | Edwards Lifesciences Corp | 67 | |
Brian Caveney | Laboratory | 47 | |
Dominic Andreano | Mednax Inc | 52 | |
William McDowell | Cigna Corp | N/A | |
Scott Ullem | Edwards Lifesciences Corp | 57 | |
Kevin Smith | Mednax Inc | N/A | |
Kristen Lauria | Cigna Corp | 51 | |
David Guilmette | Cigna Corp | 51 | |
Jason Sadler | Cigna Corp | 55 | |
Samuel Eberts | Laboratory | 57 | |
Mark Boxer | Cigna Corp | 59 |
Management Performance
Return On Equity | 0.0716 | ||||
Return On Asset | 0.0331 |
Inovalon Holdings Money Managers
Paige MD, Chief Officer | ||
Keith Dunleavy, Chairman of the Board, CEO | ||
June Duchesne, Chief Legal Officer and Corporate Secretary | ||
Jason Rosenberg, Chief Strategic Development Officer | ||
Kim Collins, Sr Communications | ||
Jason Capitel, COO | ||
Eron Kelly, Co Pres | ||
Denise Fletcher, Independent Director | ||
Ingrid Olsen, Chief Officer | ||
Thomas Kloster, CFO | ||
Daniel Mendelson, President of Avalere Health | ||
Christopher Greiner, Chief Product and Operations Officer | ||
Joseph Rostock, CTO | ||
Andre Hoffmann, Independent Director | ||
William Green, Director | ||
Beverly Allen, Chief Counsel | ||
Lee Roberts, Independent Director | ||
Shauna Vernal, Chief Legal Officer and Corporate Secretary | ||
Eric Sullivan, VP Strategies | ||
Mark Pulido, Independent Director | ||
Hulus Alpay, VP Relations | ||
Jonathan Boldt, Vice President - Finance | ||
Geoff Charron, Chief Officer | ||
Daniel Rizzo, Chief Innovation Officer | ||
John Burgin, Chief Product Officer | ||
Robert Wychulis, President | ||
Isaac Kohane, Director | ||
Peter Bock, Chief Administrative Officer | ||
William Teuber, Independent Director | ||
Jonathan CPA, Chief Officer | ||
Christopher Hand, Chief Growth Officer |
Inovalon Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Inovalon Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0716 | ||||
Return On Asset | 0.0331 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.14 % | ||||
Current Valuation | 7.22 B | ||||
Shares Outstanding | 77.17 M | ||||
Shares Owned By Insiders | 3.99 % | ||||
Shares Owned By Institutions | 75.85 % | ||||
Number Of Shares Shorted | 4.45 M | ||||
Price To Earning | 188.89 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovalon Holdings. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Inovalon Etf please use our How to Invest in Inovalon Holdings guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Inovalon Etf analysis
When running Inovalon Holdings' price analysis, check to measure Inovalon Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovalon Holdings is operating at the current time. Most of Inovalon Holdings' value examination focuses on studying past and present price action to predict the probability of Inovalon Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovalon Holdings' price. Additionally, you may evaluate how the addition of Inovalon Holdings to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
The market value of Inovalon Holdings is measured differently than its book value, which is the value of Inovalon that is recorded on the company's balance sheet. Investors also form their own opinion of Inovalon Holdings' value that differs from its market value or its book value, called intrinsic value, which is Inovalon Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovalon Holdings' market value can be influenced by many factors that don't directly affect Inovalon Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovalon Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovalon Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovalon Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.